proglumide has been researched along with Disease Models, Animal in 25 studies
Proglumide: A drug that exerts an inhibitory effect on gastric secretion and reduces gastrointestinal motility. It is used clinically in the drug therapy of gastrointestinal ulcers.
proglumide : A racemate composed of equal amounts of (R)- and (S)-proglumide. A non-selective CCK antagonist that was used primarily for treatment of stomach ulcers, but has been replaced by newer drugs.
N(2)-benzoyl-N,N-dipropyl-alpha-glutamine : A dicarboxylic acid monoamide obtained by formal condensation of the alpha-carboxy group of N-benzoylglutamic acid with dippropylamine.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In order to elucidate the involvement of cholecystokinin (CCK) in the regulation of anxiety, the author examined the effects of the selective non-peptide CCKB receptor antagonist LY288513 on freezing behavior induced by conditioned fear stress, an animal model of anxiety." | 7.70 | [Behavioral and neurochemical study on the role of the brain cholecystokinin system in anxiety]. ( Izumi, T, 1998) |
| "Trypsinogen activation peptide (TAP) concentration and alpha 2-macroglobulin-trypsin complex (alpha 2M-T) activity were measured in two experimental models of acute pancreatitis in rats to evaluate the significance of activation of trypsinogen in acute pancreatitis." | 7.69 | Activation of trypsinogen in experimental models of acute pancreatitis in rats. ( Hayakawa, T; Hirao, S; Kitagawa, M; Nakae, Y; Naruse, S; Yamamoto, R, 1995) |
| "Involvement of endogenous cholecystokinin (CCK) in the development of acute pancreatitis induced in rats by closed duodenal loop (CDL) was examined, and the effects of the potent and specific CCK receptor antagonist loxiglumide on this model of acute pancreatitis were evaluated." | 7.68 | Involvement of endogenous cholecystokinin in the development of acute pancreatitis induced by closed duodenal loop. ( Itoh, H; Koide, M; Okabayashi, Y; Otsuki, M; Tani, S, 1993) |
| "We evaluated the effects of a new cholecystokinin (CCK) receptor antagonist, loxiglumide, in a model of mild pancreatitis induced by repeated injections of cerulein and in a severe necrotizing form of pancreatitis induced by retrograde ductal injection of sodium taurocholate (NaTc) in rats." | 7.68 | Effect of a new cholecystokinin receptor antagonist loxiglumide on acute pancreatitis in two experimental animal models. ( Fujii, M; Itoh, H; Nakamura, T; Okabayashi, Y; Otsuki, M; Tani, S, 1990) |
| "The effects of the cholecystokinin (CCK)-receptor antagonist proglumide, the protease inhibitor gabexate, and the hormones secretin and cholecystokinin-octapeptide (CCK-8) were studied in a model of acute hemorrhagic pancreatitis induced by feeding mice a choline-deficient, ethionine-supplemented (CDE) diet." | 7.67 | Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis. ( Ferrell, LD; Grendell, JH; Liddle, RA; Niederau, C, 1986) |
| "Proglumide (Pgm) is a known cholecystokinin (CCK) antagonist and any changes in the level of CCK and in the number of CCK receptors has been linked with SE." | 5.40 | Ameliorating effects of proglumide on neurobehavioral and biochemical deficits in animal model of status epilepticus. ( Ahmad, M; Wadaan, MA, 2014) |
| "Two murine models were used to determine whether CCK receptor blockade with proglumide could prevent and reverse histologic and biochemical features of chronic pancreatitis: the 6-week repetitive chronic cerulein injection model and the modified 75% choline-deficient ethionine (CDE) diet." | 3.96 | Cholecystokinin Receptor Antagonist Therapy Decreases Inflammation and Fibrosis in Chronic Pancreatitis. ( Cao, H; Ciofoaia, V; Kallakury, B; Nadella, S; Smith, JP; Tucker, RD, 2020) |
| " Mechanical allodynia elicited by burn injury was partially reversed by meloxicam (5 mg/kg), gabapentin (100 mg/kg) and oxycodone (3 and 10 mg/kg), while thermal allodynia and gait abnormalities were only significantly improved by amitriptyline (3 mg/kg) and oxycodone (10 mg/kg)." | 3.83 | Transcriptomic and behavioural characterisation of a mouse model of burn pain identify the cholecystokinin 2 receptor as an analgesic target. ( Deuis, JR; Lewis, RJ; Vetter, I; Yin, K, 2016) |
| "In order to elucidate the involvement of cholecystokinin (CCK) in the regulation of anxiety, the author examined the effects of the selective non-peptide CCKB receptor antagonist LY288513 on freezing behavior induced by conditioned fear stress, an animal model of anxiety." | 3.70 | [Behavioral and neurochemical study on the role of the brain cholecystokinin system in anxiety]. ( Izumi, T, 1998) |
| "Trypsinogen activation peptide (TAP) concentration and alpha 2-macroglobulin-trypsin complex (alpha 2M-T) activity were measured in two experimental models of acute pancreatitis in rats to evaluate the significance of activation of trypsinogen in acute pancreatitis." | 3.69 | Activation of trypsinogen in experimental models of acute pancreatitis in rats. ( Hayakawa, T; Hirao, S; Kitagawa, M; Nakae, Y; Naruse, S; Yamamoto, R, 1995) |
| "Effects of a new cholecystokinin (CCK)A-receptor antagonist, T-0632 [sodium (S)-1-(2-fluorophenyl)-2, 3-dihydro-3-[(3-isoquinolinylcarbonyl) amino]-6-methoxy-2-oxo-1H-indole-3-propanoate], on caerulein-induced and pancreatic duct ligation-induced pancreatitis models were studied and compared with the CCKA-receptor antagonist loxiglumide and the orally active protease inhibitor camostate, respectively." | 3.69 | Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis. ( Endo, T; Kume, E; Nagasaki, M; Shikano, T; Taniguchi, H; Yomota, E, 1997) |
| "Involvement of endogenous cholecystokinin (CCK) in the development of acute pancreatitis induced in rats by closed duodenal loop (CDL) was examined, and the effects of the potent and specific CCK receptor antagonist loxiglumide on this model of acute pancreatitis were evaluated." | 3.68 | Involvement of endogenous cholecystokinin in the development of acute pancreatitis induced by closed duodenal loop. ( Itoh, H; Koide, M; Okabayashi, Y; Otsuki, M; Tani, S, 1993) |
| "We evaluated the effects of a new cholecystokinin (CCK) receptor antagonist, loxiglumide, in a model of mild pancreatitis induced by repeated injections of cerulein and in a severe necrotizing form of pancreatitis induced by retrograde ductal injection of sodium taurocholate (NaTc) in rats." | 3.68 | Effect of a new cholecystokinin receptor antagonist loxiglumide on acute pancreatitis in two experimental animal models. ( Fujii, M; Itoh, H; Nakamura, T; Okabayashi, Y; Otsuki, M; Tani, S, 1990) |
| "The effects of the cholecystokinin (CCK)-receptor antagonist proglumide, the protease inhibitor gabexate, and the hormones secretin and cholecystokinin-octapeptide (CCK-8) were studied in a model of acute hemorrhagic pancreatitis induced by feeding mice a choline-deficient, ethionine-supplemented (CDE) diet." | 3.67 | Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis. ( Ferrell, LD; Grendell, JH; Liddle, RA; Niederau, C, 1986) |
| "Proglumide (Pgm) is a known cholecystokinin (CCK) antagonist and any changes in the level of CCK and in the number of CCK receptors has been linked with SE." | 1.40 | Ameliorating effects of proglumide on neurobehavioral and biochemical deficits in animal model of status epilepticus. ( Ahmad, M; Wadaan, MA, 2014) |
| "Ulcerative colitis is associated with altered contractile activity and transit time of colon." | 1.33 | Proglumide attenuates experimental colitis in rats. ( Al Moutaery, A, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.00) | 18.7374 |
| 1990's | 6 (24.00) | 18.2507 |
| 2000's | 8 (32.00) | 29.6817 |
| 2010's | 4 (16.00) | 24.3611 |
| 2020's | 5 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Gay, MD | 3 |
| Cao, H | 4 |
| Shivapurkar, N | 3 |
| Dakshanamurthy, S | 1 |
| Kallakury, B | 3 |
| Tucker, RD | 4 |
| Kwagyan, J | 1 |
| Smith, JP | 4 |
| Nadella, S | 2 |
| Ciofoaia, V | 2 |
| Safronenka, A | 2 |
| Liu, FH | 1 |
| Malchiodi, ZX | 1 |
| Kroemer, A | 1 |
| Huber, M | 1 |
| Kruger, AJ | 1 |
| Kroemer, AHK | 1 |
| Ahmad, M | 1 |
| Wadaan, MA | 1 |
| Jia, D | 1 |
| Yamamoto, M | 1 |
| Otsuki, M | 3 |
| Yin, K | 1 |
| Deuis, JR | 1 |
| Lewis, RJ | 1 |
| Vetter, I | 1 |
| Yucel, T | 1 |
| Gonullu, D | 1 |
| Orhan Gurer, A | 1 |
| Duzman, R | 1 |
| Nihat Koksoy, F | 1 |
| Yilmaz, N | 1 |
| Sit, M | 1 |
| Wu, CL | 1 |
| Hung, CR | 1 |
| Chang, FY | 1 |
| Pau, KY | 1 |
| Wang, PS | 1 |
| Netto, CF | 1 |
| Guimarães, FS | 1 |
| Latorre, M | 1 |
| Bartolomé-Nebreda, JM | 1 |
| García-López, MT | 1 |
| González-Muñiz, R | 1 |
| Herranz, R | 1 |
| Del Río, J | 1 |
| Cenarruzabeitia, E | 1 |
| Al Moutaery, A | 1 |
| Nakae, Y | 1 |
| Naruse, S | 1 |
| Kitagawa, M | 1 |
| Hirao, S | 1 |
| Yamamoto, R | 1 |
| Hayakawa, T | 1 |
| Tani, S | 3 |
| Itoh, H | 2 |
| Koide, M | 1 |
| Okabayashi, Y | 2 |
| Taniguchi, H | 1 |
| Yomota, E | 1 |
| Kume, E | 1 |
| Shikano, T | 1 |
| Endo, T | 1 |
| Nagasaki, M | 1 |
| Izumi, T | 1 |
| Satake, K | 1 |
| Kimura, K | 1 |
| Saito, T | 1 |
| Friedrich, AE | 1 |
| Gebhart, GF | 1 |
| Ogura, Y | 1 |
| Matsuda, S | 1 |
| Itho, M | 1 |
| Sasaki, H | 1 |
| Tanigawa, K | 1 |
| Shimomura, M | 1 |
| Manni, L | 1 |
| Lundeberg, T | 1 |
| Tirassa, P | 1 |
| Aloe, L | 1 |
| Nakamura, T | 1 |
| Fujii, M | 1 |
| Niederau, C | 1 |
| Liddle, RA | 1 |
| Ferrell, LD | 1 |
| Grendell, JH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1/2 Trial to Test the Safety of a CCK Receptor Antagonist, Proglumide, in Management of Chronic Pancreatitis Symptoms and Pain for 12 to 24 Months[NCT05551858] | Phase 1/Phase 2 | 32 participants (Anticipated) | Interventional | 2022-11-17 | Recruiting | ||
| Phase 1 Study to Test Safety and Dose of Proglumide as an Anti-fibrotic Agent in Non-alcoholic Steatohepatitis (NASH)[NCT04152473] | Phase 1 | 18 participants (Actual) | Interventional | 2019-12-13 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
25 other studies available for proglumide and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome.
Topics: Animals; Bacteria; Disease Models, Animal; Gastrointestinal Microbiome; Gene Expression Regulation; | 2022 |
Cholecystokinin Receptor Antagonist Therapy Decreases Inflammation and Fibrosis in Chronic Pancreatitis.
Topics: Animals; Ceruletide; Chronic Disease; Disease Models, Animal; Fibrosis; Inflammation; Lipase; Mice; | 2020 |
Targeting the Cholecystokinin Receptor: A Novel Approach for Treatment and Prevention of Hepatocellular Cancer.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Chemokines, CC; Cholecystokinin; Diet, High-Fa | 2021 |
A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Choline Deficiency; Disease Models, Animal; Ep | 2020 |
Ameliorating effects of proglumide on neurobehavioral and biochemical deficits in animal model of status epilepticus.
Topics: Animals; Cognition; Disease Models, Animal; Glutathione; Lithium; Male; Motor Activity; Oxidative St | 2014 |
Effect of endogenous cholecystokinin on the course of acute pancreatitis in rats.
Topics: Administration, Oral; Animals; Biomarkers; Bombesin; Cell Proliferation; Cholecystokinin; Disease Mo | 2015 |
Transcriptomic and behavioural characterisation of a mouse model of burn pain identify the cholecystokinin 2 receptor as an analgesic target.
Topics: Amines; Amitriptyline; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Gabapentin; Gai | 2016 |
The effects on diet, anastomotic type, and loxiglumide on gastric emptying following gastrojejunostomy.
Topics: Anastomosis, Surgical; Animals; Cholecystokinin; Disease Models, Animal; Enteral Nutrition; Female; | 2009 |
Involvement of cholecystokinin receptor in the inhibition of gastrointestinal motility by estradiol in ovariectomized rats.
Topics: Animals; Benzodiazepinones; Cholecystokinin; Devazepide; Disease Models, Animal; Estradiol; Female; | 2002 |
Anxiogenic effect of cholecystokinin in the dorsal periaqueductal gray.
Topics: Analysis of Variance; Animals; Anti-Anxiety Agents; Anxiety; Appetite Depressants; Cell Count; Disea | 2004 |
Pharmacological study of IQM-97,423, a potent and selective CCK1 receptor antagonist with protective effect in experimental acute pancreatitis.
Topics: Acute Disease; alpha-Amylases; Animals; Binding, Competitive; Cerebral Cortex; Cholecystokinin; Deva | 2004 |
Proglumide attenuates experimental colitis in rats.
Topics: Acetic Acid; Animals; Anti-Ulcer Agents; Cholecystokinin; Colitis, Ulcerative; Disease Models, Anima | 2005 |
Activation of trypsinogen in experimental models of acute pancreatitis in rats.
Topics: Acute Disease; alpha-Macroglobulins; Animals; Benzamidines; Ceruletide; Disease Models, Animal; Guan | 1995 |
Involvement of endogenous cholecystokinin in the development of acute pancreatitis induced by closed duodenal loop.
Topics: Acute Disease; Amylases; Animals; Cholecystokinin; Disease Models, Animal; Duodenum; Lipase; Male; P | 1993 |
Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis.
Topics: Acute Disease; Amylases; Animals; Ceruletide; Disease Models, Animal; Dogs; Esters; Female; Gabexate | 1997 |
[Behavioral and neurochemical study on the role of the brain cholecystokinin system in anxiety].
Topics: Animals; Anxiety; Biogenic Monoamines; Brain; Cholecystokinin; Disease Models, Animal; Hormone Antag | 1998 |
Therapeutic effects of loxiglumide on experimental acute pancreatitis using various models.
Topics: Animals; Ceruletide; Disease Models, Animal; Female; Hormone Antagonists; Male; Mice; Pancreatitis, | 1999 |
Effects of spinal cholecystokinin receptor antagonists on morphine antinociception in a model of visceral pain in the rat.
Topics: Analgesics; Anesthesia; Animals; Benzodiazepinones; Colitis; Colon; Devazepide; Disease Models, Anim | 2000 |
Inhibitory effect of loxiglumide (CR 1505), a cholecystokinin receptor antagonist, on N-nitrosobis(2-oxopropyl) amine-induced biliary carcinogenesis in Syrian hamsters.
Topics: Adenocarcinoma, Papillary; Animals; Autoradiography; Biliary Tract Neoplasms; Carcinogens; Cholecyst | 2002 |
Role of cholecystokinin-8 in nerve growth factor and nerve growth factor mRNA expression in carrageenan-induced joint inflammation in adult rats.
Topics: Animals; Arthritis, Experimental; Carrageenan; Disease Models, Animal; Drug Interactions; Enzyme-Lin | 2002 |
Effect of a new cholecystokinin receptor antagonist loxiglumide on acute pancreatitis in two experimental animal models.
Topics: Acute Disease; Animals; Ceruletide; Cholecystokinin; Disease Models, Animal; Glutamine; Male; Pancre | 1990 |
Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis.
Topics: Acute Disease; Amylases; Animals; Cholecystokinin; Choline Deficiency; Disease Models, Animal; Ethio | 1986 |
Experimental acute pancreatitis induced by excessive doses of caerulein in rats; protective and therapeutic effects of trypsin inhibitor urinastatin and CCK receptor antagonist CR1392.
Topics: Acute Disease; Animals; Ceruletide; Disease Models, Animal; Dose-Response Relationship, Drug; Glutam | 1988 |